Generic Rx Projected New Generic Releases

---

COMING SOON!

Generic Rx

Helping you effectively manage your inventory

Projected New Generic Releases

Page 1 of 2 Dosage Form

Earliest Possible Generic Launch Date*

Injection

3/2/13

Pain Management

Tablets

5/14/13

Zolmitriptan

Pain Management

Tablets

5/14/13

Rilutek®

Riluzole

ALS

Tablets

6/18/13

Temodar® (capsules)

Temozolomide

Oncology

Capsules

8/11/13

Cellcept® (Intravenous)

Mycophenolate Mofetil

Prophylaxis of Organ Rejection

Injection

9/15/13

Lidoderm®

Lidocaine

Pain Management

Patch

9/15/13

Advicor®

Lovastatin, Niacin

Cardiovascular

Tablets

9/20/13

Niaspan®

Niacin

Cardiovascular

Tablets

9/20/13

Aciphex®

Rabeprazole Sodium

Gastrointestinal

Tablets

11/8/13

Cymbalta®

Duloxetine Hydrochloride

CNS

Capsules

12/11/13

Vanos®

Fluocinonide

Dermatology

Cream

12/15/13

Locoid Lipocream®

Hydrocortisone Butyrate

Dermatology

Cream

Q4 2013

Aplenzin® (348mg)

Bupropion Hydrobromide

CNS

Tablets

Q4 2013

Astepro® (0.15%)

Azelastine Hydrochloride

Respiratory

Nasal Spray

Pending a Settlement Agreement

Clarinex-D® 24 Hour

Desloratadine, Psuedoephedrine sulfate

Respiratory

Tablets

Pending a Settlement Agreement

Adenoscan®

Adenosine

Cardiovascular

Injection

Pending FDA Approval

Atacand®

Candesartan cilexetil

Cardiovascular

Tablets

Pending FDA Approval

Diovan®

Valsartan

High Blood Pressure

Tablets

Pending FDA Approval

Lescol® XL

Fluvastatin Sodium

Cholesteral Lowering

ER Tablets

Pending FDA Approval

Vidaza®

Azacitidine

Oncology

Injection

Pending FDA Approval

Brand Name

Generic Name

Indication

Reclast®

Zoledronic acid

Metabolic Disorders

Zomig® (tablets)

Zolmitriptan

Zomig-ZMT®

Pending Litigation/FDA Approval

*NOTE: Product release dates are influenced by evolving market conditions, legal actions and other factors. Launch dates are anticipated, but not guaranteed. The products on this list are those for which the probability of a generic being approved and launched are almost certain. There are other products that could launch during this time frame, but due to uncertainties, they are not included. For full prescribing information, please see manufacturer’s package insert.

If you do not wish to receive future fax notifications, or have received this in error, please call 866.481.9644.

March 2013

Day 181 Alert

Generic Rx

Helping you effectively manage your inventory

Exclusivity End Date Alerts

Page 2 of 2

These generic items will lose exclusivity in the near future. As a result, pricing in the market will likely decrease at that time. Use this alert as a reminder to manage your inventory accordingly. Brand Name

Generic Name

FazaClo® ODT

Clozapine ODT

Diovan HCT®

Valsartan and Hydrochlorothiazide

Launch Date 9/4/12

End Date Early March 2013

9/24/12

Late March 2013

Metadate CD®

Methylphenidate HCl CD

9/28/12

Late March 2013

Comtan®

Entacapone

10/3/12

Early April 2013

Gabitril® (2,4 mg only)

Tiagabine HCL

10/19/12

Mid April 2013

Atacand HCT® (32-25mg only)

Candesartan Cilexetil HCTZ (32-25mg only)

12/5/12

Early June 2013

Propecia®

Finasteride

1/3/13

Late June 2013

Maxalt MLT®

Rizatriptan Benzoate ODT

1/3/13

Late June 2013

Lysteda®

Tranexamic Acid

1/7/13

Early July 2013

Duetact®

Pioglitazone HCl/Glimepiride

1/9/13

Early July 2013

Opana ER®

Oxymorphone HCI ER

2/5/13

Early July 2013

NOTE: Dates subject to change

If you do not wish to receive future fax notifications, or have received this in error, please call 866.481.9644.

March 2013